Antibiotic therapy and prophylaxis in COPD

Respiratory Medicine: COPD Update

Volumn 2, Issue 4, 2007, Pages 124-132

  Blasi, Francesco ^a   Tarsia, Paolo ^a   Pappalettera, Maria ^a   Saporiti, Matteo ^a   Aliberti, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antibiotics; COPD; Exacerbations; Prophylaxis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; ROXITHROMYCIN; TELITHROMYCIN; TETRACYCLINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DRUG MEGADOSE; GRAM NEGATIVE BACTERIUM; HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SPUTUM;

EID: 33846674811     PISSN: 17450454     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedu.2006.10.002     Document Type: Review

References (52)

1. Sapey E., and Stockley R.A. COPD exacerbations: aetiology. Thorax 61 (2006) 250-258
2. Groenewegen K.H., Schols A.M., and Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbations of COPD. Chest 124 (2003) 459-467
3. Monso E., Ruiz J., Rosell A., et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152 (1995) 1316-1320
4. Soler N., Torres A., Ewig S., et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157 (1998) 1498-1505
5. Moller L., Timens W., Van Der Bij W., et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 157 (1998) 950-956
6. Bandi V., Apicella M., Moson E., et al. Non-typeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 164 (2001) 2114-2119
7. Sethi S., Evans N., Grant B.J., and Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347 (2002) 465-471
8. Sethi S., Wrona C., Grant B.J., and Murphy T.F. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 169 (2004) 448-453
9. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?. Proc Am Thorac Soc 1 (2004) 109-114
10. Murphy T.F., Brauer A.L., Grant B.J., and Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 172 (2005) 195-199
11. Murphy T.F. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 19 (2006) 225-230
12. Hurst J.R., Perera W.R., Wilkinson T.M., et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 (2006) 71-78
13. Berenson C.S., Murphy T.F., Wrona C.T., and Sethi S. Outer membrane protein P6 of non-typeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines. Infect Immunol 73 (2005) 2728-2735
14. Chin L.C., Manzel L.J., Lehman E.E., et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 172 (2005) 85-91
15. White A.J., Gompertz S., Bayley D., et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58 (2003) 680-685
16. Bach P.B., Brown C., Gelfand S.E., and McCrory D.C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 134 (2001) 600-620
17. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD004403.
18. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
19. Stockley R.A., O'Brien C., Pye A., and Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117 (2000) 1638-1645
20. Allegra L., Blasi F., Diano P.L., et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 99 (2005) 742-747
21. Evans A.T., Husain S., Durairaj L., Sadowski L.S., Charles-Damte M., and Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 359 (2002) 1648-1654
22. Allegra L., Blasi F., de Bernardi B., Cosentini R., and Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 14 (2001) 149-155
23. Nouira S., Marghli S., Belghith M., Besbes L., Elatrous S., and Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 358 (2001) 2020-2025
24. Woodhead M., Blasi F., Ewig S., Huchon G., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26 (2005) 1138-1180
25. Monso E., Rosell A., Bonet G., et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 13 (1999) 338-342
26. Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., and Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116 (1999) 40-44
27. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., and Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 113 (1998) 1542-1548
28. Mogulkoc N., Karakurt S., Isalska B., et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 160 (1999) 349-353
29. Blasi F., Legnani D., Lombardo V., et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 6 (1993) 19-22
30. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., and Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program 1997-1999. Clin Infect Dis 32 Suppl 2 (2001) S81-S93
31. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN and the Alexander project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired lower respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46.
32. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121
33. Doern G.V., and Brown S.D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 48 (2004) 56-65
34. Ho P.L., Yung R.W., Tsang D.N., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong-Kong multicentre study in 2000. J Antimicrob Chemother 48 (2001) 659-665
35. Thornsberry C., Ogilvie P., Holley H.J., and Sahm D. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study. Antimicrob Agents Chemother 43 (1999) 2612-2623
36. Schito G.C., Debbia E.A., and Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 46 Suppl T1 (2000) 3-9
37. Doern G., Jones R., Pfaller M., and Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 43 (1999) 385-389
38. Lonks J.R., Garau J., Gomez L., Xercavins M., Ochoa de Echaguen A., Gareen I.F., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35 (2002) 556-564
39. Anzueto A., Niederman M.S., Haverstock D.C., and Tillotson G.S. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. Clin Ther 19 (1997) 989-1001
40. Dewan N.A., Rafique S., Kanwar B., et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 117 (2000) 662-671
41. Wilson R., Kubin R., Ballin I., et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 44 (1999) 501-513
42. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., and Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 94 (2000) 18-27
43. DeAbate C.A., Mathew C.P., Warner J.H., Heyd A., and Church D. The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 94 (2000) 1029-1037
44. Adams S.G., Melo J., Luther M., and Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117 (2000) 1345-1352
45. Cabello H., Torres A., Celis R., et al. Bacterial colonization of the distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 10 (1997) 1137-1144
46. Soler N., Ewig S., Torres A., et al. Airway inflammation and bronchial microbial patterns with stable chronic obstructive pulmonary disease. Eur Respir J 14 (1999) 1015-1022
47. Banerjee D., Khair O.A., and Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 23 (2004) 685-691
48. Hurst J.R., Wilkinson T.M., Perera W.R., et al. Relationship among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 127 (2005) 1219-1226
49. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 (2003) 1090-1095
50. Murphy T.F., Brauer A.L., Schiffmacher A.T., and Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 266-272
51. Black P, Staykova T, Chacko E, Ram FS, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. The Cochrane Library, Issue 1, 2003.
52. Sethi S., Anzueto A., Wilson R., et al. Placebo-controlled, double-blind trial of chronic, intermittent 'pulse' therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data. Eur Respir J 28 S50 (2006) 842s (abstract)